![](https://servier.ca/wp-content/uploads/sites/24/2024/02/servier.ca-Servier-Group-2022-23-Financial-Results-confirm-its-2025-trajectory-to-achieve-its-2030-ambition_1200x630.png)
Servier, an independent international pharmaceutical group, has published its financial results for the 2022-2023 financial year and highlighted the milestones that marked the year, particularly in R&D.
Key Highlights
- Consolidated sales revenue of €5.327 billion, up 9.2% (+12% at CERi) compared to 2021-2022, driven by strong growth in international sales
- Performance fueled by growth in sales volumes of both brand-name medicines (€4.041 billion, +9.4%) and generics (€1.286 billion, +8.8%)
- Strong performance in oncology sales, which exceeded the symbolic €1 billion mark
- Major breakthroughs in oncology, addressing high unmet medical needs
- A promising and robust R&D pipeline, bringing hope to patients
![Olivier Laureau, Servier's CEO: In 2022-2023, Servier performed well on the strength of an innovative portfolio in oncology and a strong incremental innovation strategy in cardiometabolism and venous diseases.](https://servier.ca/wp-content/uploads/sites/24/2024/02/In-2022-2023-Servier-performed-well-on-the-strength-of-an-innovative-portfolio-in-oncology-and-a-strong-incremental-innovation-strategy-in-cardiometabolism-and-venous-diseases.png)
07/02/2024